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ABSTRACT
Fatty Acid Synthase (FASN), a key enzyme of de novo lipogenesis, is upregulated 
in many cancers including colorectal cancer (CRC); increased FASN expression is 
associated with poor prognosis. Potent FASN inhibitors (TVBs) developed by 3-V 
Biosciences demonstrate anti-tumor activity in vitro and in vivo and a favorable 
tolerability profile in a Phase I clinical trial.
However, CRC characteristics associated with responsiveness to FASN inhibition 
are not fully understood. We evaluated the effect of TVB-3664 on tumor growth in 
nine CRC patient-derived xenografts (PDXs) and investigated molecular and metabolic 
changes associated with CRC responsiveness to FASN inhibition.
CRC cells and PDXs showed a wide range of sensitivity to FASN inhibition. TVB-
3664 treatment showed significant response (reduced tumor volume) in 30% of 
cases. Anti-tumor effect of TVB-3664 was associated with a significant decrease in a 
pool of adenine nucleotides and alterations in lipid composition including a significant 
reduction in fatty acids and phospholipids and an increase in lactosylceramide and 
sphingomyelin in PDXs sensitive to FASN inhibition. Moreover, Akt, Erk1/2 and AMPK 
were major oncogenic pathways altered by TVBs. 
In summary, we demonstrated that novel TVB inhibitors show anti-tumor 
activity in CRC and this activity is associated with a decrease in activation of Akt 
and Erk1/2 oncogenic pathways and significant alteration of lipid composition of 
tumors. Further understanding of genetic and metabolic characteristics of tumors 
susceptible to FASN inhibition may enable patient selection and personalized 
medicine approaches in CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the 2nd most common 
cause of cancer death in the United States [1]. Despite 
advances in our understanding of the molecular basis of 
CRC and the increasing number of targeted therapies, 
treatment frequently remains disappointing, particularly 
for advanced stages of disease [2, 3]. New approaches 
to treat advanced CRC are urgently needed to improve 
clinical outcomes.
Metabolic reprogramming is a hallmark of cancer, 
controlling various aspects of malignant development and 
progression. Activation of de novo lipogenesis in cancer 
cells, which is increasingly recognized as one of the 
characteristics of aggressive cancers [4], correlates with a 
poorer prognosis and shorter disease-free survival in many 
tumor types including CRC [5, 6].
Abnormally elevated de novo lipogenesis provides 
cancer cells with membrane building blocks, signaling 
lipid molecules, and posttranslational modifications 
of proteins, as well as energy to support rapid cell 
proliferation [7]. Our published studies demonstrate an 
increase in expression of fatty acid synthase (FASN), a 
key enzyme of de novo lipogenesis, with advancing stages 
of CRC, suggesting an important role of de novo lipid 
synthesis in progression of this disease [6, 8].
The tumor-associated expression of FASN and its 
pro-tumorigenic functions characterized in multiple studies 
make this enzyme an attractive target for anti-cancer 
therapy [5–7, 9]. In recent years, several compounds have 
been reported to inhibit the enzymatic activity of FASN 
and reduce growth of malignant cells; however, some of 
them exhibit pharmacological limitations or induce weight 
loss, preventing their development as systemic drugs 
[9, 10]. In contrast, potent FASN inhibitors developed by 
3-V Biosciences demonstrate anti-tumor activity in vitro 
and in vivo and a favorable tolerability profile in a Phase 
I clinical trial in patients bearing solid tumors [4, 11, 12]. 
The effect of FASN inhibitors on CRC progression and 
CRC characteristics associated with responsiveness to 
FASN inhibition are not yet known.
Patient-derived xenograft (PDX) models including 
CRC PDXs retain the intratumoral clonal heterogeneity, 
tumor microenvironment, and morphology of the parent 
tumor through passages in mice [2, 13–15] and are one of 
the most valuable models for preclinical drug evaluation 
[16]. In this study, we tested the effect of TVB-3664 and 
its analogs (3V-Biosciences) on tumor growth in nine CRC 
PDX models, primary CRC cells, and established CRC cell 
lines. We demonstrated that CRC PDXs and CRC cells 
show a wide range of sensitivity to FASN inhibition and 
that high levels of FASN expression are associated with 
increased sensitivity of cancer cells to TVB inhibitors in 
vitro. Furthermore, our results suggest that Akt, Erk1/2 and 
AMPK are major oncogenic pathways altered by FASN 
inhibitors. Finally, we showed that FASN inhibition in PDX 
tumor tissues is associated with a significant decrease in 
the pool of adenine nucleotides (AXP) which play a crucial 
role in a variety of metabolic functions of proliferating 
cells [17]. Moreover, TVB-3664 treatment significantly 
decreased the abundance of FA and phospholipids such 
as phosphatidylcholines and phosphatidic acids and 
significantly increased the levels of lactosylceramide and 
sphingomyelin in analyzed PDX models.
Together, our findings provide evidence of 
biological activity of TVB compounds in CRC and warrant 
further investigation to understand the mechanisms of 
resistance to FASN inhibition and improve efficacy of 
FASN-targeted therapy.
RESULTS
TVB inhibitors show anti-tumor activity in 
established CRC cell lines and primary CRC 
cells
FASN and de novo lipogenesis, its cognate 
pathway, are critical components of tumor cell survival 
and proliferation for a wide range of cancers [18]. Recent 
studies showed that TVB-3166—an orally available, 
reversible, potent, and selective FASN inhibitor—
decreases viability in multiple tumor cell lines from 
solid and hematopoietic tumor types and tumor growth 
of patient-derived non-small-cell lung cancer xenograft 
tumors [12]. To evaluate the effect of this inhibitor in 
CRC, a panel of 13 CRC cell lines was treated with 0.2 μM 
of TVB-3166 for 7 days with medium and drug change 
on day 4 and cellular proliferation assessed by cell count. 
The CRC cell lines exhibited a wide range of sensitivity 
to FASN inhibition, with low expression of FASN in 
SW480, SW620 and LIM2405 associated with resistance 
to FASN inhibition. Increased resistance of CRC cells 
to FASN inhibition appears to be associated with an 
increase in basal level of activation of pAkt and pAMPK. 
Furthermore, a subset of cell lines sensitive to TVB-3166 
showed enrichment in the cell lines with a high level of 
active beta-catenin (Figure 1A). Similar responses were 
observed when CaCo2, HT29 and LIM2405 cells were 
treated with TVB-3664 and TVB-3693, analogs of TVB-
3166, in cell line specific medium supplemented with 
10% FBS for 7 days without medium change (Figure 1B; 
Supplementary Figure 1A). In comparison, the increase 
in efficacy of FASN inhibitors was due to culturing cells 
without a medium change, suggesting that an availability 
of exogenous FAs may in part compensate for the effect of 
these inhibitors on cellular proliferation. Consistent with 
our previous findings using shRNA-mediated knockdown 
of FASN [6], pharmacological inhibition of FASN with 
TVB-3166 induced apoptosis in HCT116 and HT29 cells 
(Supplementary Figure 1B) suggesting that TVB inhibitors 
have cytotoxic effect on CRC cells.
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To further evaluate the effect of FASN inhibition in 
CRC, we treated two primary cell lines (Pt 93 and Pt 130) 
established from PDX tumors [19] with different doses of 
TVB-3166, TVB-3664 and TVB-3693. Primary CRC cells 
used in this study were established from PDX tumors and 
were used as 2D cultures (Supplementary Figure 1C–1D). 
We observed a significant decrease in cellular 
proliferation in both cell lines (Figure 1C and 1E). 
However, the response to FASN inhibition was more 
prominent in the Pt 93 cells and associated with a significant 
decrease in expression of active β-catenin, c-Myc, 
survivin and induction of PARP cleavage (Figure 1D). 
No changes in pAkt and pAMPK were observed due 
to TVB treatment in this cell line. In contrast, FASN 
inhibition in Pt 130 cells lead to activation of pAMPK and 
pAkt pathways as well as an increase in active β-catenin 
(Figure 1F). These data further suggest that activation of 
Akt and AMPK pathways can be associated with reduced 
sensitivity to FASN inhibition in CRC cells.
These data demonstrate that TVB inhibitors have 
anti-tumor activity in CRC and suggest that the level of 
FASN expression and the activity of oncogenic pathways 
such as Akt and AMPK may determine the responsiveness 
of CRC to FASN inhibition.
Figure 1: CRC cell lines exhibit a wide range of sensitivity to FASN inhibition. (A) A panel of CRC cell lines was treated 
with TVB-3166 (0.2 μM) for 7 days in their normal medium supplemented with 10% FBS. Medium and drug were changed on day 4. 
Proliferation was determined by cell count. Data shown as percent response to FASN inhibition. (B) The two most sensitive (CaCo2 and 
HT29) and the most resistant (LIM2405) cell lines were treated with multiple concentrations of TVB-3664 for 7 days without medium 
change and the number of cells was counted (*p < 0.05). (C, E) Primary CRC cells Pt 93 and Pt 130 were treated with multiple concentrations 
of TVBs for 7 days and proliferation was determined by cell count. *p < 0.05. (D, F) Primary CRC cells were treated for 24 h (Pt 93) and 
7 days (Pt 93 and Pt 130) with TVB inhibitors and cell lyses were subjected to western blot analysis.
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PDXs show a wide range of sensitivity to FASN 
inhibition
Expression of FASN is significantly upregulated 
in a stage-dependent manner in CRC [6]. To evaluate the 
expression of FASN in a population of patients treated at 
the University of Kentucky, we analyzed FASN expression 
in matched normal colon mucosa and tumor tissues from 
56 patients with Stage I-IV CRC who had surgery at UK 
Chandler Medical Center. The tissue microarray results 
demonstrated that 9% of cases were negative for FASN 
expression in tumor tissues and 91% of tumors had a 
significant increase in FASN expression (Supplementary 
Figure 2A).
TVB-3166 inhibits tumor growth of patient-
derived non-small-cell lung cancer xenograft tumors 
[12, 20]. To evaluate the effect of TVB-3664, a newer 
analog of TVB-3166 [20], in CRC, we established 
nine CRC PDX models in NOD-SCID-IL2rg-/- (NSG) 
mice using specimens collected from patients who had 
undergone surgery for resection of primary CRC or 
CRC metastasis (Figure 2A). Pt 2377PT/Pt 2377LM 
and Pt 2449PT/Pt 2449LM models represent matching 
primary tumor (PT) and liver metastasis (LM) tissues 
collected from the same patient and established in NSG 
mice (Supplementary Table 1). PDX models established 
from patient tissues were designated generation 0 (G0); 
subsequent generations established through propagation 
of tumor tissues from mouse to mouse were designated 
G1 and G2. Consistent with previous reports [13, 21], 
the morphology of established CRC PDXs resembled 
the morphology of the parent tumor through passaging in 
mice (Supplementary Figure 2B–2C). To ensure that PDX 
models and established primary cells recapitulate genetic 
characteristics of patient tumors, the mutational status 
of 198 oncogenes was analyzed in patient tissues, PDX 
tissues and primary cells using next-generation sequencing 
(Table 1 and Supplementary Table 2).
Immunohistological analysis of patient tumor 
tissues showed that all cases were positive for FASN 
expression, with the lowest expression observed in Pt 
2377PT and LM (Figure 2B). Similar to our in vitro 
data (Figure 1), PDX models exhibited a wide range of 
sensitivity to FASN inhibition. TVB-3664 treatment led 
to a significant reduction in tumor volume and tumor 
weight in Pt 2614, Pt 2449PT, and Pt 2402 PDX models, 
with an average reduction in tumor weight of 30%, 37.5% 
and 51.5%, respectively (Figure 2C). Interestingly, TVB-
3664 treatment of the Pt 2387 model led to a significant 
35% decrease in tumor volume at week 4 followed by 
resistance, which developed at week 5. A small decrease 
in tumor volume and tumor size was observed in Pt 
2449LM, Pt 2568, and Pt 2607 PDX models treated 
with TVB-3664, but these changes were not significant 
(Figure 2C, 2D). TVB-3664 treatment had an adverse 
effect and accelerated tumor growth in Pt 2377PT and LM 
PDXs (Figure 2E). Consistent with the previous report that 
TVB compounds are well tolerated in vivo [12], we did not 
observe any drug-related toxicity in our animal studies. 
With the exception of the Pt 2402 model, no significant 
weight loss was noted at the end of the treatment period 
(Figure 2C–2E).
We did not observe clear correlation between levels 
of FASN expression in patient tissues and the response 
to FASN inhibition. However, similar to in vitro studies 
(Figure 1), low expression of FASN in Pt 2377PT and 
LM was associated with resistance to FASN inhibition. 
Interestingly, Pt 2377PT and LM PDXs showed an adverse 
effect to long-term treatment with TVB-3664; however, 
these changes were not significant in Pt 2377PT. We noted 
that Pt 2377PT and LM models have co-existing KRAS 
and PI3KCA mutations (Figure 2E, Table 1). The PI3KCA 
mutation was also present in Pt 2387, which developed 
resistance during treatment (Figure 2D, Table 1). TP53 
mutation was present in PDX models that were sensitive 
to FASN inhibition (Table 1). Even though we did 
not determine significant correlation between tumor 
mutational backgrounds and response to FASN inhibition, 
these findings will be tested in future studies.
Together, these findings suggest that TVB-3664 as 
a monotherapy has anti-tumor activity in CRC; however, 
studies with a larger number of cases are required to 
establish reliable biomarkers to identify a population of 
patients that is sensitive to FASN-targeted therapy.
Activation of Akt and AMPK pathways 
is associated with resistance to TVB-3664 
treatment in PDX models and primary CRC 
cells
The dependence of tumors on de novo lipid synthesis 
for their metabolic requirements, survival and growth 
suggests that FASN expression level may determine 
a tumors’ response to FASN inhibition [4, 22, 23]. 
Moreover, our published studies demonstrate that 
inhibition of FASN alters multiple signaling pathways 
including the Akt and AMPK pathways [6, 8].
To evaluate the correlation between FASN 
expression, activation of major oncogenic pathways, and 
tumor response in vivo, we analyzed the levels of FASN, 
pAkt, pAMPK, pErk1/2, and TIP47 in tumor tissues 
from G0 PDX models. Western blot analysis showed 
expression of FASN in all established PDXs, with the 
highest expression in Pt 2449PT and LM and in Pt 2402. 
We found higher levels of pAkt and pAMPK among PDX 
models that were resistant to FASN inhibition. The level 
of TIP47, a marker for lipid droplets [24], was also higher 
in more resistant models (Figure 3A). Pharmacological 
inhibition of FASN leads to a decrease in activation of 
pAkt  [20, 25, 26]. However, inhibition of FASN also 
induces pro-survival Akt and ERK signaling in K-Ras-
driven cancer cells [27]. To analyze the effect of TVB-
Oncotarget24791www.oncotarget.com
Figure 2: Effect of TVB-3664 on tumor growth in CRC PDX models. (A) Schematic representation of study design. 
(B) Representative IHC images taken from resected patient tumor tissues stained for FASN expression. (C) PDX models sensitive to 
TVB-3664 treatment. Tumor response to FASN inhibition is shown as a fold change in tumor volume over time. Middle row shows 
corresponding tumor size at the end of the experiment. Bottom row shows corresponding fold change in weight of animals over time. 
Animals were treated daily with 3 mg/kg (Pt 2614 and Pt 2449PT) or 6 mg/kg (Pt 2402 and Pt 2449LM) of TVB-3664 by oral gavage 
(*p < 0.05; Pt 2377PT and Pt 2377LM are established from matched primary and liver metastasis tissues from Pt 2377). No response to 
TVB-3664 treatment was observed in PDX Pt 2449LM. (D) PDX models resistant to FASN inhibition. Tumor response to FASN inhibition 
is shown as a fold change in tumor volume over time. Middle row shows corresponding tumor size at the end of the experiment. Bottom 
row shows corresponding fold change in weight of animals over time. Animals were treated daily with 3 mg/kg of TVB-3664 by oral 
gavage (*p < 0.05). (E) Accelerated tumor growth in Pt 2377 PDX models treated with 3 mg/kg of TVB-3664. Tumor response to FASN 
inhibition is shown as a fold change in tumor volume over time in PDX models established from primary CRC (left) and liver metastasis 
tumors (right) Pt 2377. Middle row shows corresponding tumor size at the end of the experiment. Bottom row shows corresponding fold 
change in weight of animals over time (*p < 0.05).
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3664 treatment on activity of these pathways, control and 
TVB-3664 treated PDX tumors were subjected to western 
blot analysis. The response to FASN inhibition was 
associated with a decrease in activation of pErk1/2 and 
TIP47 and induction of LC3 (an autophagy marker [28]) 
in the Pt 2402 model (Figure 3B). No significant changes 
in pAMPK or pAkt activation were observed in the other 
PDX models that were identified as sensitive to FASN 
inhibition. In contrast, TVB-3664 treatment induced 
activation of pAkt and pAMPK but decreased the level of 
TIP47 in the Pt 2387 model (Figure 3C), suggesting that 
activation of these pathways may be potential mechanisms 
of resistance to FASN inhibition. The analysis of tumor 
samples from TVB-3664 treated Pt 2377PT and LM 
models showed an increase in pErk1/2 and activation of 
pAMPK, respectively (Figure 3D).
All together, these data suggest that activation of 
AMPK, Akt and Erk1/2 pathways can be a mechanism of 
resistance to FASN inhibition.
Inhibition of FASN is associated with a 
significant decrease in a pool of adenine 
nucleotides in PDX tumors
Stable knockdown of FASN decreases cellular 
respiration and ATP level under metabolic stress conditions in 
CRC cell lines [8]. Our studies using HCT116 cells, control 
and stable FASN knockdown, labeled with 13C6-glucose for 
24 h showed that knockdown of FASN decreases lactate 
production by 20% and lowers the lactate to glucose ratio 
(by 13C-Lac /13C-Glc) 22% (p = 0.0026). Furthermore, 
FASN knockdown decreased the level of excreted lactate 
and acetate (p = 0.06) in this cell line (Supplementary 
Figure 3A–3D). To investigate the effect of TVB-3664 on 
tumor metabolism in PDX tumors, we performed untargeted 
metabolomics on tissue samples from Pt 2449PT, Pt 2402, 
and Pt 2614, which responded to FASN inhibition. Pt 2449PT 
and Pt 2402 mice were fasted 16 h then injected i.p. with 
2 g/kg–1 body mass of 13C6-glucose 1 h before sacrifice, as 
previously described [29], which allows SIRM tracing of 
cellular metabolites in control and treated tumors. Mice with 
Pt 2614 tumors were fasted for 16 h but 13C6-glucose labeling 
was not performed. To prepare samples for SIRM analysis, 
tumor tissues were ground and polar and lipid fractions were 
extracted and analyzed using nuclear magnetic resonance and 
mass spectrometry.
Analysis of plasma metabolites revealed that 
inhibition of FASN in Pt 2449PT and Pt 2402 led to 
an increase in 13C labeled glucose and total glucose in 
plasma samples of mice treated with TVB-3664 versus 
control. In Pt 2614, we observed a significant increase 
in the level of acetate (but not glucose) in plasma from 
mice treated with TVB-3664, suggesting a different 
metabolic response to FASN inhibition in this PDX 
model. In contrast to our data from FASN knockdown 
cells, no significant changes were observed in the levels 
of 13C lactate or total lactate between control and TVB-
3664 treated groups (Figure 4A); however, we observed a 
similar decrease in the lactate to glucose ratio (13C-Lac 
/13C-Glc) in Pt 2402 and Pt 2449PT (Figure 4B)
The analysis of FASN-mediated changes in polar 
metabolites in tumor tissues showed a significant decrease 
in the pool of free adenine nucleotides (ATP + ADP + 
AMP = AXP) in all three PDX models analyzed; however, 
these changes did not reach statistical significance in the 
Pt 2614 model (Figure 4C). Furthermore, inhibition of 
FASN significantly decreased the levels of myo-Inositol 
(a metabolite that plays an important role in cell signaling 
and is a component of structural lipids [30]), in Pt 2402 
and Pt 2449PT, but not Pt 2614 (Figure 4D).
Table 1: Mutational profile of PDX models
 APC BRAF KRAS NRAS PI3K EGFR FGFR TP53
 Pt 93*  mut mut      
 Pt 130*  mut mut    mut  
 Pt 2449PT mut mut       
 Pt 2449LM  mut   mut  mut mut
 Pt 2402        mut
 Pt 2614 mut   mut    mut
 Pt 2607  mut    mut   
 Pt 2568 mut       mut
 Pt 2387 mut  mut  mut   mut
 Pt 2377PT mut  mut  mut    
 Pt 2377LM mut  mut  mut    
Mutational status of 198 cancer genes was assessed in tumor tissues obtained from CRC patients and in established PDX 
models and primary cells (*) by NSG sequencing. Mutational status of key oncogenes involved in CRC development and 
progression is shown (see Methods).
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Together, these data suggest that FASN inhibition is 
associated with an increase in glucose metabolism and a 
reduction in a pool of adenine nucleotides.
Inhibition of FASN leads to significant changes 
in lipid composition in CRC
Stable knockdown of FASN is associated with 
a significant decrease in de novo palmitate synthesis 
[6] and formation of lipid droplets [8], suggesting 
that expression of FASN and its activity significantly 
affects lipid composition and storage in cancer cells. 
Consistently, analysis of HT29 cells (control and stable 
FASN knockdown) for incorporation of 13C6-glucose tracer 
into lipids showed that inhibition of FASN is associated 
with a 40% decrease in de novo synthesized triglycerides 
and phospholipids such as phosphatidylethanolamines 
and phosphatidylcholines, which are major components 
of biological membranes [31] (Supplementary Figure 4A).
To assess the effect of TVB-3664 on lipid 
metabolism in PDX models, we first analyzed the levels 
of palmitate in plasma samples collected from control and 
TVB-3664 treated mice prior to their sacrifice. Plasma 
samples were analyzed by mass spectroscopy as previously 
described [6]. We observed a significant decrease in total 
palmitate levels in Pt 2402, Pt 2449LM, Pt 2614 and Pt 
2377LM but not in others (Figure 5A), suggesting that 
there is no correlation between pharmacological inhibition 
of FASN and the level of total palmitate in plasma. 
Furthermore, we analyzed the lipid fractions extracted 
from control and TVB-3664 treated tumors for Pt 2449PT, 
Pt 2402 and Pt 2614 models. TVB-3664 treatment led to a 
distinct lipid profile in each model as shown by principal 
component analysis (Supplementary Figure 4B–4D). The 
table of lipid species that significantly changed in each 
PDX model is shown in Supplementary Figure 4E. The 
binominal analysis of common changes in lipids among 
these three PDX models showed that FASN inhibition is 
associated with a significant decrease in the levels of fatty 
acids and phospholipids such as phosphatidylcholines and 
phosphatidic acids and a significant increase in levels of 
lactosylceramide and sphingomyelin (Figure 5B, 5C).
Figure 3: Expression of FASN and activation of FASN-associated oncogenic pathways in PDX models. (A) Western blot 
analysis of tissues from PDX models (all G1; Pt 2387 G2) showing expression/activation of major oncogenic pathways associated with 
de novo lipogenesis. Cases sensitive to FASN inhibition are shown in bold (arrows). (B) Western blot analysis of tumor tissues from Pt 
2402 treated with 6 mg/kg of TVB-3664 daily for 5 weeks. (C) Western blot analysis of tissues the Pt 2387 model treated with 3 mg/kg of 
TVB-3664 daily for 5 weeks. (D) Western blot analysis of tumor tissues from Pt 2377PT and LM treated with 3 mg/kg of TVB-3664 daily 
for 4 weeks.
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In summary, these data further suggest that anti-
cancer effect of FASN inhibition is associated with a 
significant impact on lipid composition.
DISCUSSION
An increase in de novo lipid synthesis is the common 
characteristic of many tumors including colorectal 
cancer [5]. Inhibition of FASN decreases proliferation 
and diminishes metastatic capabilities of cancer cells in 
multiple tumor models [4, 6, 18, 32]. Currently, novel 
FASN inhibitors developed by 3V-Biosciences are being 
evaluated in Phase I/II clinical trial [33]. TVB-2640 
demonstrates prolonged stable disease when given in 
monotherapy and partial response when combined with 
paclitaxel in KRASmut non-small cell lung, ovarian, and 
breast cancer patients [18]. However, the effect of FASN 
inhibition in CRC and potential mechanisms of resistance 
to FASN inhibition are still not fully understood. This 
study is the first to evaluate the effect of TVB inhibitors in 
CRC using PDX models and primary CRC cells.
Evaluation of FASN expression in a CRC tissue 
microarray showed that 91% of patients who have 
undergone surgery at the University of Kentucky are 
positive for FASN expression, which is consistent with 
previously published data [34]. All nine PDX models 
Figure 4: Inhibition of FASN alters metabolites levels in PDX models sensitive to TVB-3664. (A) Changes in plasma 
metabolites in Pt 2402, Pt 2449PT and Pt 2614 PDXs. (B) Representative figures of NMR spectra obtained from analysis of plasma from 
the Pt 2402 model (control vs TVB-3664 treated). Levels of AXP (C) and m-Ins-2 (D) in tumor tissues from PDX models sensitive to 
TVB-3664 (p < 0.05) (see Methods).
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used for evaluation of TVB-3664 in the current study were 
positive for FASN expression. Treatment of CRC PDXs 
with TVB-3664 as a monotherapy led to a significant 
decrease in tumor volume in 30% of cases suggesting 
that the presence of FASN expression does not predict 
response to FASN inhibitors. The maximum reduction in 
tumor weight in response to TVB-3664 treatment achieved 
in our study was 50% which is significantly less than the 
>80% reduction in tumor growth in non-small-cell lung 
cancer PDXs treated with TVB-3166 [12] suggesting that 
lung cancer may be more susceptible to FASN inhibition.
Consistent with the study showing variability in 
sensitivity to TVB-3166 among 90 cell lines from different 
tumor types [12], our in vitro studies demonstrated a 
significant variability in responses to FASN inhibition in 
CRC. In contrast to reported data from other tumor types 
[12, 35], we noted a correlation between high expression 
of FASN and increased sensitivity to FASN inhibition in 
established CRC cell lines. However, we did not identify a 
similar correlation in in vivo studies, suggesting that other 
factors such diet and/or the ability of particular tumors to 
metabolize endogenous fatty acids may contribute to the 
Figure 5: Inhibition of FASN alters lipid composition in PDX models sensitive to TVB-3664. (A) Total plasma palmitate 
levels in control and TVB-3664-treated mice measured by mass spectrometry. FA (50 μl of a 1 μM C17) was added to 50 μl of plasma as 
an internal standard. Half of each sample was saponificated and derivatized and total palmitate measured by mass spectrometry (*p < 0.05). 
(B–C) FASN-mediated changes in lipid classes common among Pt 2402, Pt 2449PT and Pt 2614 PDX models. Lipid classes were evaluated 
by grouping the lipids to a class, and within each class setting lipids with fold-change >0 as successes, and <0 as failures, and testing the 
ratio of successes to failures to 0.5 using a two-sided binomial test. The reported value for the binomial test is the log-ratio of the calculated 
proportion of successes over 0.5 (see Methods).
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tumor’s response to TVBs as well. Similar to LIM2405, 
which was not sensitive to FASN inhibition due to very 
low expression of the enzyme in this cell line, low levels 
of FASN expression in Pt 2377PT and LM PDXs were 
associated with resistance to TVB-3664 and prolonged 
treatment led to acceleration of tumor growth. All together, 
in vitro and in vivo data suggest that evaluation of FASN 
expression is important for selection of candidates to 
FASN-targeted therapy, but the tumor being positive for 
FASN expression is not sufficient to predict response to 
this therapy.
In attempt to correlate the response of FASN 
inhibition to the mutational profile of tumors, we 
assessed the mutational status of 198 cancer-related 
genes. Studies performed by 3V- Biosciences [12] have 
shown an association of FASN inhibitor sensitivity with 
KRAS mutation status in lung cancer cell lines, but not 
in analysis of 29 CRC cell lines. Consistently, we did 
not identify any correlation between presence of KRAS 
mutation and response to FASN inhibition. Furthermore, 
PI3K/Akt signaling has been linked to FASN expression 
in many tumor types [26, 27, 36, 37]. Despite the 
low number of cases analyzed in this study, we noted 
enrichment of mutant PI3K in PDXs resistant to FASN 
inhibition. In contrast to the previously published study 
which showed no correlation between PI3K status and 
CRC cell lines sensitive to FASN inhibition [12], our data 
from analysis of cell lines and PDX models treated with 
TVB inhibitors suggest that PI3K mutational status and 
activation of Akt downstream may affect the response of 
CRC cells to FASN inhibition. Our findings are supported 
by other reports showing that activation of the PI3K-Akt 
axis in response to FASN inhibition may be a potential 
mechanism of resistance to FASN inhibition [26, 27]. The 
role of PI3K/Akt pathway in resistance to FASN inhibition 
is currently being investigated in our laboratory.
Dysregulation of p53 tumor suppressor gene is one of 
the most frequent events contributing to transformation of 
normal cells to CRC and is associated with the aggressive 
and metastatic features of this disease [36]. We noted the 
presence of a mutation in TP53 genes in all PDX models 
sensitive to FASN inhibition suggesting a potential link 
between the TP53 status and the response to TVB-3664. 
To investigate other possible markers of FASN 
sensitivity, the effect of TVB-3664 on the composition 
of metabolites and lipids was analyzed in 3 PDX models 
sensitive to FASN inhibition. In agreement with our 
reports and others [8, 18, 35], FASN inhibition led to a 
decrease in the levels of fatty acids, phospholipids, and 
triacylglycerols. Our finding that a high level of TIP47 
is associated with resistance to TVB-3664 suggests 
that tumors with higher levels of stored lipids are more 
resistant to FASN inhibition.
The tumor-suppressing signaling lipid ceramide 
is elevated upon FASN inhibition in 231MFP cells [12] 
and this is consistent with our data showing increased 
levels of ceramide and hexaceramide in Pt 2402 and Pt 
2449PT, respectively. Our results also show an increase 
in levels of lactosylceramide and sphingomyelin in TVB-
3664 sensitive tumors, which has not been previously 
reported. Sphingolipids are a class of bioactive lipids that 
are key modulators of multiple pathophysiologic processes 
including tumorigenesis. Our ongoing studies investigate 
the role of FASN-mediated sphingolipid metabolism in 
CRC progression and metastasis.
Analysis of metabolites, showing a decrease in 
a pool of AXPs and Inositol in TVB-3664 treated PDX 
tumors, supports our previously published data that 
FASN promotes survival of CRC cells via upregulation of 
cellular respiration [8].
Combination of FASN inhibitors with other 
therapeutic agents can make cells sensitive to other drugs 
or can lead to synergetic effect [18]. Findings in this study 
provide evidence of activation of signaling pathways such 
as AMPK and Akt in response to FASN inhibition. 
Therefore, combination of FASN inhibitors with 
inhibitors of Akt or AMPK pathways may be a potential 
therapeutic strategy for CRC. Moreover, our studies 
suggest that inhibition of de novo fatty acid synthesis 
should be combined with dietary changes or with other 
therapeutic agents to prevent compensatory mechanisms 
by exogenous lipids. A better understanding of the relative 
contribution of endogenous and exogenous lipids to 
malignant transformation and cancer progression would 
further advance the development of new therapeutic 
approaches to target lipid metabolism in CRC.
MATERIALS AND METHODS
Colon cancer primary and established cell lines
Primary colon cancer Pt 93, Pt 130 and Pt 2387 
cultures were isolated and established from PDX tumors 
as previously described [38]. Cells were maintained as 
monolayer culture in DMEM supplemented with 10% 
FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–
streptomycin.
CRC cell lines were authenticated using STR DNA 
profiling in March 2016 (Genetica, Cincinnati, OH). 
Primary Pt 93 and Pt 130 cells were authenticated as 
unique human cell lines (Genetica). The mutation profiles 
of these cell lines were determined using targeted (a panel 
of 198 genes) NGS (UKC Genomics_OGSRF). TVB-
3664, TVB-3166 and TVB-5693 inhibitors were provided 
by 3V-Biosciences (Menlo Park, CA). The treatment 
regimen for in vitro studies is based on previously 
published studies [12, 20].
TMA analysis
Immunoreactivity score of FASN expression was 
analyzed in matched normal colon mucosa and tumor 
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tissues from patients diagnosed with Stage I-IV CRC who 
had surgery at UK Chandler Medical Center (TMA ID 
BH15991A, n = 57 normal and 56 tumor tissues). Scoring 
was carried out blindly by a pathologist. Immunoreactivity 
score was determined by multiplication of the values for 
staining intensity (0, no staining; 1, weak; 2, moderate; 3, 
strong staining) and the values for percentage of positive 
tumor cells (0, no positive cells; 1, 0–10%; 2, 11–50%; 3, 
51–100% positive).
Tissue collection and in vivo studies
Tissues were obtained from consented patients 
with Stage II-IV CRC who had undergone surgery at UK 
Medical Center (IRB # 16-0439-P2H). 6–8-week-old 
NSG mice (NOD.Cg-Prkdc Il2rg /SzJ) from The Jackson 
Laboratory (Bar Harbor, ME, USA) were used for PDX 
models. All procedures were performed using protocols 
approved by the UK Animal Care and Use Committee. 
Briefly, CRC tissues (2–5 mm) obtained from CRC 
patients of both sexes were implanted subcutaneously into 
their flanks in a small pocket surgically created under the 
skin. Established tumors were designated as generation 0 
(G0). Tumor tissues from G0 were minced and mixed with 
Matrigel to ensure homogeneous distribution of tissues 
among mice and allow implantation of an equal volume of 
tumor tissues into the flank. To preserve histopathological 
and genomic characteristics of clinical CRC tumors and 
recapitulate the differential responses of CRC tumors 
to FASN inhibitors, all established PDX models were 
treated at G1 with exception of the Pt 2387 case, which 
was treated at G2. When tumors reached 100 mm3, the 
mice were randomized according to animal weight and 
tumor size. For evaluation as monotherapy, treatment 
(n = 5) and control (n = 5) groups were given TVB-3664 
(3–6 µg/kg) vs vehicle (30% PEG400) by oral gavage 
daily for 4–6 weeks. Tumors were measured once per 
week by a digital caliper and tumor volume was calculated 
using the formula: TV = width2 × length × 0.52 as 
previously described [12]. Tumor weight was measured at 
the end of the experiment. Blood samples were collected 
through cardiac puncture at the time of sacrifice.
Mice were fasted and then injected i.p. with 2 g 
kg–1 body mass of 13C6-glucose 16 h prior to sacrifice 
as previously described [29], to allow SIRM tracing of 
cellular metabolites of tumors. 1 h after injection, blood 
samples were collected and separated into plasma and 
blood cells by centrifugation (4° C, 3,500 × g, 15 min). 
Mice were euthanized and tumor tissue was collected for 
IHC and flash frozen immediately in liquid N2 for protein 
and metabolic analysis.
In vivo data analysis
PDX treatment data are shown as the mean and SD 
for the vehicle and TVB groups and statistical significance 
determined by a two-sided, two-sample t-test with 5% 
significance. For combination treatment, statistical 
significance was determined based on a one-way ANOVA 
with 5% significance. Analysis of tumor volume entailed 
a comparison at the last follow-up time using ANOVA 
in addition to linear mixed models for analysis of tumor 
growth over time and calculation of an adjusted aAUC and 
associated confidence interval to quantify tumor growth 
inhibition between each treated versus vehicle group. We 
employed a linear mixed model with a random effects term 
for the PDX model and fixed effects term for treatment 
group to perform an overall comparison of tumor volume 
across treatment groups and PDX models.
Tissue extractions for metabolic studies
Frozen tissues were ground in liquid N2 to <10 µm 
particles in a 6750 Freezer/Mill (Retsch, Inc., Newtown, 
PA) and extracted simultaneously for soluble and lipidic 
metabolites as previously described [39].
Nuclear magnetic resonance analysis
NMR spectra were obtained on an Agilent DD2 
14.1 T spectrometer equipped with a 3-mm inverse triple 
resonance HCN cold probe. The 1D proton spectra were 
recorded at 288 k with an acquisition time of 2 s and a 
4 s relaxation delay, during which the residual HOD 
resonance was irradiated. 1D 1H[13C]HSQC spectra were 
recorded with an acquisition time of 0.25 s and a 1.75 s 
relaxation delay.
Internal DSS-d6 was used as a chemical shift 
reference and for absolute quantification. MNOVA 
(Mrestrelab Research, Santiago de Compostela, Spain) 
was used for NMR spectral processing. After phasing and 
baseline correction, metabolites were quantified using 
the peak fitting routines in MNOVA, and assigned using 
in-house databases [40]. Isotopomers were quantified 
as absolute and fractional enrichments as previously 
described [41–43]. Assigned metabolites were normalized 
to mg protein determined by BCA analysis.
Fourier transform mass spectrometry (FT-MS) 
analysis
A solution of chloroform/methanol (2:1, v/v) 
containing 1 mM butylated hydroxytoluene was used to 
dissolve the lipid extracts. MS analysis was performed using 
an Orbitrap Fusion Tribrid (Thermo Fisher Scientific, San 
Jose, CA, USA) attached to a TriVersa NanoMate (Advion 
Biosciences, Ithaca, NY, USA) using a “D” electrospray 
chip (nozzle inner diameter 4.1 μm) and a cooling unit 
to keep the samples at 4° C. For negative and positive 
ion mode analysis aliquots of the dissolved lipid extracts 
were diluted with methanol and ammonium formate 
in 2-propanol/methanol/chloroform. Nanoelectrospray 
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ionization used 1.6 kV with a 0.6 psi head pressure in 
positive ion mode, and 1.5 kV and a 0.5 psi head pressure in 
the negative mode. All data were recorded in profile mode 
using a 100 ms maximum injection time, automated gain 
control at 2.5 × 105, five microscans, and a target resolution 
of 450,000 (FWHM at m/z 200). The manufacturer’s default 
standard recommendations for the Orbitrap Fusion Tribrid 
tuning and calibration was used to achieve a mass accuracy 
of 0.5 ppm or less. A previously described software package 
developed in-house, Precalculated Exact Mass Isotopologue 
Search Engine (PREMISE), was used to make assignments 
and the isotopologue distributions for the various lipid 
classes [44]. The data were further processed to remove 
naturally occurring 13C enrichment in lipid species using 
the protocol developed by Moseley [45].
Metabolic data analysis
Polar fraction analysis: The Wilcoxon rank-sum test 
was used to compare the abundance of each metabolite 
between TVB and control groups. The method proposed 
by Storey et al. [46] was used to adjust for multiple 
comparisons and calculate the false discovery rate 
q-value. Data analysis was performed using R (version 
3.3.1). Metabolites with q-value < 0.05 were considered 
statistically significant.
Lipid analysis 
Assigned positive and negative lipid intensities were 
filtered based on HPD sites calculated from the raw peak 
lists for each sample. Lipid intensities were normalized 
by total intensities in each sample, and log-transformed 
after adding a small positive value that was 10e-3 smaller 
than the smallest intensity observed. Lipids present in 
2/3 of either the control or TVB treated samples were 
kept. For each patient, the average log-intensity in the 
control samples was subtracted from the control and TVB 
samples, resulting in a log fold-change of TVB to control 
for a given patient sample.
Individual lipids were evaluated by two-sided t-test 
on the TVB samples compared to zero. Lipid classes were 
evaluated by grouping the lipids to a class, and within each 
class setting lipids with fold-change >0 as successes, and 
<0 as failures, and testing the ratio of successes to failures 
to 0.5 using a two-sided binomial test. The reported value 
for the binomial test is the log-ratio of the calculated 
proportion of successes over 0.5. All data processing was 
carried out in R 3.3.2.
Next generation sequencing
NGS was performed on DNA from patient tissues 
and matched PDXs and primary cells. Briefly, library 
preparation was performed using the Agilent Bravo NGS 
workstation and Agilent SureSelect XT Library Prep Kit 
according to the manufacturer’s instructions (Agilent 
Technologies Inc., Santa Clara, CA). Extracted genomic 
DNA was quantified using the Qubit dsDNA HS Assay 
(Life Technologies, Illkirch, France). DNA quality was 
assessed using the Agilent 2200 TapeStation Genomic 
Screentape and reagents (Agilent Technologies Inc., Santa 
Clara, CA). Genomic DNA samples (500 ng) were sheared 
to fragment sizes of 170–200 base pairs using a Covaris 
E220 instrument (Covaris, Woburn, MA). Samples were 
adaptor-ligated and amplified for 10 cycles using a 
GeneAmp 9700 thermocycler (Applied Biosystems, Foster 
City, CA). The DNA was then purified using 1.8× volume 
AMPure XP beads (Beckman Coulter, Brea, CA). 750 ng 
of each amplified library was hybridized with biotinylated 
RNA baits comprising a custom panel of 198 clinically 
relevant oncology-related genes (Solid Tumor NGS 
Panel v1 Genomics Core Laboratory, UK, Lexington, 
KY). The hybridization was run overnight at 65° C and 
was followed by DNA capture with streptavidin beads. 
Captured libraries were amplified for 12 cycles with 
indexing primers and cleaned with 1.8× volume AMPure 
XP beads. Libraries are pooled at 4 nM and loaded at 9 pM 
onto the HiSeq 2500 as per manufacturer’s instructions for 
paired-end sequencing, with a run length of 100 bp.
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